# Research timeline and gaps: MOTS-c as a Metabolic Healthspan Peptide

Selected publication milestones, not an exhaustive history or discovery priority claim.

**2015 — 2015:12S-rRNA-region peptide candidate and controlled mouse glucose/clamp/diet experiments; genomic origin and supplied-peptide function enter the model separately.** [Original PMID25738459](https://pubmed.ncbi.nlm.nih.gov/25738459/).

**2018 — 2018:stress-induced nuclear localization and AMPK-dependent transcription in cells; cellular retrograde signaling is distinguished from human treatment.** [Original PMID29983246](https://pubmed.ncbi.nlm.nih.gov/29983246/).

**2019 — 2019:human intralipid/insulin and training responses expose context-dependent circulating-marker regulation rather than peptide administration.** [Original PMID31066084](https://pubmed.ncbi.nlm.nih.gov/31066084/).

**2020 — 2020:aging men show opposite plasma/muscle directions, challenging a simple systemic deficiency account.** [Original PMID32182209](https://pubmed.ncbi.nlm.nih.gov/32182209/).

**2021 — 2021:late-life male-mouse grip/gait/walking benefit alongside human exercise-induced marker change; overall survival extension remains nonsignificant.** [Original PMID33473109](https://pubmed.ncbi.nlm.nih.gov/33473109/).

**2021 — 2021:WT/K14Q sequence contrasts and Japanese-ancestry genotype associations map sex/activity dependence rather than universal genotype causality.** [Original PMID33468709](https://pubmed.ncbi.nlm.nih.gov/33468709/).

**2024 — 2024:CK2 binding, inhibitor/ASO necessity and tissue-dependent responses strengthen targeted pharmacology; human genotype components retain overlap limitations.** [Original PMID39559755](https://pubmed.ncbi.nlm.nih.gov/39559755/).

**2024 — 2024:older Korean male K14Q carriers show higher muscle/strength, requiring prospective population/context reconciliation.** [Original PMID39457696](https://pubmed.ncbi.nlm.nih.gov/39457696/).

**2026 — 2026:mouse PGC1alpha/AMPK-dependent mitochondrial effects and human no-gradient exercise measurement sharpen target and source questions.** [Original PMID41520850](https://pubmed.ncbi.nlm.nih.gov/41520850/).

**2026 — 2026:AMPK activation can accompany worseMSCrepair, while obesity/bariatric data (PMID41551324) show that peptide levels need not normalize with metabolic improvement.** [Original PMID42324588](https://pubmed.ncbi.nlm.nih.gov/42324588/).

## Research gaps

Native transcript export, cellular translation machinery and quantitative peptide identity need direct orthogonal tests.

No examined primary native-MOTS-c human administration study establishes metabolic function plus durable healthspan.

Physiological concentrations and synthetic pharmacologic dosing need a validated exposure bridge.

Late-life functional benefit and overall lifespan are different; natural-aging replication across backgrounds/species and sexes is incomplete.

K14Q cohort findings depend on sex, age and activity and can point in opposite directions across populations;12S-rRNA and mitochondrial linkage alternatives require selective tests.

Circulating peptide can rise with metabolic stress and remain elevated after improvement; tissue sources and renal handling are unresolved.

AMPK/mitochondrial marker activation can coexist with worse repair; functional and adverse outcomes must be prespecified.

Shared cohorts, peptide reagents and assay platforms require independent error-mode assessment rather than paper-count convergence.

## Boundary experiment

First validate native human peptide identity, quantitative exposure and translation/export separately from synthetic material. Then preregister placebo-controlled native-MOTS-c dosing in a baseline-defined human metabolic/age cohort, with pharmacokinetics, tissue-specific engagement and prespecified glucose/physical-function endpoints plus durable clinical healthspan follow-up. Prospectively stratify sex/age/genotype and independently replicate; separately use a peptide-selective production perturbation preserving12S-rRNA function to test endogenous necessity with sequence-specific rescue.